3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
7
Gynecologic
6
Thoracic
3
Gastrointestinal
3
Breast
3
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leiomyosarcoma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
26
Temozolomide
23
Doxorubicin
22
Radiotherapy
21
Filgrastim
19
Ifosfamide
15
pazopanib
14
Gemcitabine
14
Etoposide
13
Bevacizumab
13
Irinotecan
12
Cisplatin
12
Magnetic Resonance Spectroscopy
11
Imatinib Mesylate
11
Granulocyte Colony-Stimulating Factor
11
Carboplatin
11
Radiation
9
Methotrexate
9
pembrolizumab
8
fludarabine phosphate
8
Rituximab
8
Paclitaxel
8
Docetaxel
8
Cyclosporine
8
Busulfan
8
Antilymphocyte Serum
8
fludarabine
7
Vincristine
7
Radiotherapy, Intensity-Modulated
7
Mycophenolic Acid
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
rucaparib
×
Sarcoma
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts